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Abstract: Insulin resistance is a key feature of the metabolic syndrome, a cluster of medical disorders
that together increase the chance of developing type 2 diabetes and cardiovascular disease. In turn,
type 2 diabetes may cause complications such as diabetic kidney disease (DKD). Obesity is a major risk
factor for developing systemic insulin resistance, and skeletal muscle is the first tissue in susceptible
individuals to lose its insulin responsiveness. Interestingly, lean individuals are not immune to insulin
resistance either. Non-obese, non-diabetic subjects with chronic kidney disease (CKD), for example,
exhibit insulin resistance at the very onset of CKD, even before clinical symptoms of renal failure are
clear. This uraemic insulin resistance contributes to the muscle weakness and muscle wasting that
many CKD patients face, especially during the later stages of the disease. Bioenergetic failure has
been associated with the loss of skeletal muscle insulin sensitivity in obesity and uraemia, as well as in
the development of kidney disease and its sarcopenic complications. In this mini review, we evaluate
how mitochondrial activity of different renal cell types changes during DKD progression, and discuss
the controversial role of oxidative stress and mitochondrial reactive oxygen species in DKD. We also
compare the involvement of skeletal muscle mitochondria in uraemic and obesity-related muscle
insulin resistance.
Keywords: bioenergetics; energy metabolism; ATP turnover; oxidative stress; insulin signalling;
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1. Introduction
When the blood glucose concentration rises above its set point, pancreatic beta cells secrete
insulin [1], a peptide hormone that provokes an orchestrated anabolic response to the raised glucose
availability by altering the behaviour of multiple organs [2]. Skeletal muscle is a major contributor to
the systemic anabolic response, as insulin-sensitive glucose uptake by this comparably large tissue
accounts for more than 70% of the whole-body glucose disposal [3]. Most of the glucose that is
taken up by skeletal muscle is subsequently stored as glycogen, as insulin activates glycogenesis and
inhibits glycogenolysis [2]. Insulin also enhances cell growth and differentiation [4], stimulates protein
synthesis and inhibits protein breakdown [5,6] and promotes mitochondrial biogenesis [7] (Figure 1).
When higher than usual insulin levels are required to maintain glucose homeostasis, individuals are
considered to be insulin resistant. Obesity (body mass index ≥30 kg/m2) is a broadly accepted risk
factor of systemic insulin resistance [8], and loss of skeletal muscle insulin sensitivity is the first sign of
such resistance in human subjects [2]. Pancreatic beta cells compensate by increasing the production
and secretion of insulin [9], but when such compensation fails, insulin resistance will progress to type
2 diabetes (T2D). In turn, T2D may cause various complications [10], including diabetic kidney disease
(DKD—[11]). It has been estimated [12] that 609 million adults were obese in 2015, which amounts
to roughly 10% of the global population. Equally staggering, 8.2% of adults worldwide have been
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diagnosed with T2D [13], 20–40% of whom are expected to develop DKD [14]. A better mechanistic
insight into these disorders is necessary to curb their high prevalence.
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(AKT2 in skeletal muscle) pathway and the Ras-mitogen-activated protein kinase (MAPK) pathway, 
which both instruct muscle cells to engage with anabolic processes. Activated AKT2 has multiple 
effects: (i) It stimulates recruitment of the glucose transporter protein (GLUT4) to the plasma 
membrane, and is thus responsible for insulin-sensitive glucose uptake by muscle; (ii) it activates 
glycogen synthesis by inhibiting glycogen synthase kinase-3 (GSK3); (iii) it promotes mitochondrial 
biogenesis, protein synthesis, and cell growth and differentiation, effects that are all mediated 
through the stimulation of the mammalian target of rapamycin (mTOR); (iv) it suppresses protein 
breakdown by phosphorylating and thus deactivating Forkhead box O (FOXO) transcription factors 
that stimulate proteasome- and lysosome-mediated proteolysis. The MAPK pathway acts in concert 
with AKT2 to transmit insulin’s message to increase cell growth and differentiation. 
The many proposed mechanisms by which different organs lose their insulin sensitivity are 
diverse, but nutrient excess is a common factor [2]. Such excess emerges when dietary nutrient 
supply outweighs systemic energy expenditure, and is thus a key feature of obesity. At the cellular 
level, mitochondria are crucial for adjusting nutrient-fuelled ATP supply to energy expenditure, and 
changes in oxidative ATP synthesis are linked to obesity-related insulin resistance of skeletal muscle 
[16]. Skeletal muscle insulin resistance also emerges in other states than obesity. For instance, 
individuals with chronic kidney disease (CKD) exhibit low muscle insulin sensitivity even at the 
very onset of renal dysfunction [17]. This uraemic muscle insulin resistance is linked to disturbed 
protein metabolism [5], and to the loss of skeletal muscle function and mass [18]. The mean global 
prevalence of CKD is currently 13.4% [19]. As in obesity, muscle insulin resistance in CKD is 
associated with altered muscle mitochondrial function [20]. Notably, the development of kidney 
disease itself has been linked to the loss of renal insulin sensitivity [21,22] and to mitochondrial 
changes in multiple renal cell types [23,24].  
In this mini review, we discuss how renal mitochondrial activity changes in DKD and explore 
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function and dysfunction of mitochondria, we focus on their involvement in ATP synthesis, redox 
biology and oxidative stress. Effective engagement of mitochondria in these processes is influenced 
by their structural integrity, but mechanisms that ensure such integrity by regulating the dynamic 
morphology of mitochondria will not be discussed here. They have been recently reviewed expertly 
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(IRS1), which comprise a ‘critical node’ in a branched signalling network that allows interaction with
other pathways, for example those induced by cytokines [15]. Activation of this node triggers two
major protein kinase cascades, i.e., the phosp atidylinosit l-3-kinase (PI3K)—pr tei i ase (AKT2
in skeletal muscle) p thway and the Ras-mitogen-activated protein kinase (MAPK) ay, which
both instruct muscle cells to engage with anabolic processes. Activated AKT2 has multiple effects: (i) It
stimulates recruitment of the glucose transporter protein (GLUT4) to the plasma membrane, and is
thus responsible for insulin-sensitive glucose uptake by muscle; (ii) it activates glycogen synthesis
by inhibiting glycogen synthase kinase-3 (GSK3); (iii) it promotes mitochondrial biogenesis, protein
synthesis, and cell growth and differentiation, effects that are all ediated through the stimulation of
the mammalian target f rapamycin (mTOR); (iv) it suppress s pr tein breakdown by phosphorylating
and thus deactivating Forkhead box O (FOXO) transcription factors that stimulate proteasome- and
lysosome-mediated proteolysis. The MAPK pathway acts in concert with AKT2 to transmit insulin’s
message to increase cell growth and differentiation.
The many proposed mechanisms by which different organs lose their insulin sensitivity are
diverse, but nutrient excess is a common factor [2]. Such excess emerges when dietary nutrient supply
outweig s sy temic energy expend tu , and is thus a key feature of obesity. At the cellular level,
mitochondria ar crucial for adjusting nutrient-fuelled ATP supply to energy expenditure, d changes
in oxidative ATP synthesis are linked to obesity-related insulin resistance of skeletal muscle [16].
Skeletal muscle insulin resistance also emerges in other states than obesity. For instance, individuals
with chronic kidney disease (CKD) exhibit low muscle insulin sensitivity even at the very onset of renal
dysfunction [17]. This uraemic muscle insulin resistance is linked to disturbed rotein metabolism [5],
and to the loss of skeletal muscle function and mas [18]. The mean global prevalence of CKD is
currently 13.4% [19]. As in obesity, muscle insulin resistance in CKD is associated with altered muscle
mitochondrial function [20]. Notably, the development of kidney disease itself has been linked to the
loss of renal insulin sensitivity [21,22] and to mitochondrial changes in multiple renal cell types [23,24].
In this mini review, we discuss how renal mitochondrial activity changes in DKD and explore
the bioenergetics of skeletal muscle d fects that may result from kidne dise se. With respect to the
function and dysfuncti n f mitochondria, we focus on their involvem t in ATP synthesis, redox
biology and oxidative stress. Effective engagement of mitochondria in these processes is influenced
by their structural integrity, but mechanisms that ensure such integrity by regulating the dynamic
morphology of mitochondria will not be discussed here. They have been recently reviewed expertly
by others in context of nutrient metabolism [25], kidney disease [23,26] and the maintenance of muscle
mass [27].
Int. J. Mol. Sci. 2019, 20, 2751 3 of 15
2. Renal Mitochondrial Activity in Diabetic Kidney Disease
Hyperglycaemia is the most important risk factor for kidney disease in people with diabetes [11],
which explains why CKD is a prevalent microvascular complication of both T1D [28] and T2D [29].
Additional risk factors include hypertension, dyslipidaemia, insulin resistance and obesity [11], which
are all features of the metabolic syndrome that increases the likelihood of developing T2D [30]. Renal
function depends on the interplay between multiple cell types [31] and demands much energy—the
kidney’s specific resting metabolic rate is 440 kcal kg−1 day−1 [32]. Diabetic kidney disease is
characterised by filtration defects that manifest as persistent and increasing presence of protein in the
urine (albuminuria) and a progressive decline in the glomerular filtration rate that may end in complete
loss of kidney function [33]. These clinical symptoms are preceded by more silent disease stages in
which glomerular filtration is either unaffected or in fact increased [33]. However, morphological
changes to the glomeruli can be detected early in DKD [34] and include thickening of the glomerular
basement membrane, mesangial expansion, podocyte loss and hypertrophy of remaining podocytes.
Renal lesions that arise at a later stage include glomerulosclerosis and tubulointerstitial fibrosis [34].
2.1. Bioenergetics
Tubular reabsorption demands high amounts of energy, as ATP-fuelled Na+-K+ pumps establish
the ion gradients that are needed for active trans-epithelial transport [35]. Since the required ATP is
provided predominantly through oxidative phosphorylation [36], kidney function relies heavily on
mitochondria, and mitochondrial dysfunction is thus believed to be central to DKD [23]. Renal ATP
demand is raised during early-stage DKD, as hyper-filtration (cf. [33]) necessitates additional tubular
reabsorption. Increased ATP synthesis in the kidney [37] at the outset of DKD is indeed consistent
with extra energy expenditure. Interestingly, the additional ATP synthesis seems accounted for by
glycolysis [37], not oxidative phosphorylation, suggesting a shift from mitochondrial to glycolytic
ATP supply [38]. Notably, increased oxygen uptake by the kidney in early DKD is not coupled to
ATP synthesis [39]. Similarly, the increased respiration exhibited by podocytes following prolonged
exposure to 30 mM glucose, is insensitive to oligomycin and is thus not used to produce ATP [40].
Uncoupling protein-2 (UCP2) has been held responsible for the diabetes-related uncoupled respiration
in renal proximal tubular cells [41] and in mitochondria isolated from the kidney cortex [42]. However,
since the molecular and physiological functions of UCP2 remain the subject of significant debate [43],
the nature of UCP2 involvement in DKD is accordingly uncertain [42,44,45]. For instance, Ucp2 gene
polymorphisms have been linked to the glomerular filtration rate in T2D patients and to decreased
expression of renal Ucp2 [46], which is at odds with the asserted UCP2 involvement in uncoupled
respiration [41].
As DKD progresses, renal ATP synthesis [47], glucose oxidation [48] and fatty acid oxidation [49]
start to decline. Mitochondrial activity changes accordingly in primary human glomerular mesangial
cells (HMCs) after a 12-day exposure to 25 mM glucose [50]. Real-time functional bioenergetic analysis
has demonstrated that such exposure lowers both coupled and uncoupled respiration [50]. It thus
transpires that hyperglycaemia diminishes both the total and spare mitochondrial respiratory capacities
of HMCs [50]. Exposure to a high glucose concentration has similar effects on mitochondrial oxygen
uptake by immortalized proximal tubular (HK-2) cells [51]. It is thus likely that hyperglycaemia
impairs the mitochondrial ATP synthesis capacity of HMCs and HK-2 cells, although it is formally
possible that this capacity is lowered in response to decreased ATP demand during the extended
glucose exposure. Notably, decreased mitochondrial respiratory capacity coincides with increased
glycolysis in HK-2 cells but not in HMCs [51]. This contrasting glycolytic response might relate to a
dissimilar energy demand, but it is presently unclear if it reflects differences between primary and
immortalized cells, or between mesangial and tubular cells. Consistent with the effects of glucose
excess on kidney cells [50,51], peripheral blood mononuclear cells (PBMCs) from patients with DKD
have a comparably low spare respiratory capacity [50]. It has thus been suggested that systemic
mitochondrial dysfunction underpins development of DKD [50]. It seems indeed likely that a diabetic
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milieu affects multiple bodily compartments, but the causal interrelations between the respective
bioenergetic changes remain unclear.
2.2. Redox Biology and Oxidative Stress
The ATP synthesis rate of most cell types adjusts to ATP demand [16]. When metabolic fuel supply
outweighs energy expenditure, many redox enzymes attain a reduction potential that allows partial
reduction of oxygen [52] and thus formation of reactive oxygen species (ROS). For instance, at least
11 distinct mitochondrial enzymes are capable of producing ROS under reducing conditions [53].
These ROS have important physiological functions, but cause damage when they accumulate to
excess. This duality is exemplified in skeletal muscle, where hydrogen peroxide is essential for insulin
signalling, but causes oxidative stress and insulin resistance at persistently high concentrations [54].
Oxidative stress has been linked to diabetic complications [55], and a unifying pathological mechanism
identifies mitochondria as source of the responsible ROS [56,57]. Intuitively, it seems likely that chronic
hyperglycaemia disturbs the bioenergetic balance between renal energy demand and metabolic fuel
supply, thus favouring ROS generation, but it remains contentious whether the ROS originate from
mitochondria [58] or arise elsewhere, for example from activity of cytosolic NADPH oxidases [59].
Irrespective of the precise origin and molecular nature of the culprit, ROS-induced damage is indeed
evident in diabetes, as urinary oxidised guanosine (a marker of oxidative DNA damage) correlates
with mortality in T2D patients with albuminuria [60], and increases the risk of kidney disease in
T1D patients [61]. In apparent contrast, kidneys of mice with streptozotocin-induced type 1 diabetes
exhibit a lower ROS production rate—measured as in vivo oxidation of systemically administered
dihydroethidium—than their healthy counterparts [48]. Nevertheless, glomerular oxidised guanosine
and renal mitochondrial DNA (mtDNA) mutations that were detected in the diabetic mice [48] suggest
a history of oxidative stress. Pharmacological stimulation of AMP-activated protein kinase (AMPK)
increases renal ROS in these models [48], which is unexpected, as AMPK triggers antioxidant defence
mechanisms [62]. Equally surprisingly, the increased ROS production coincides with a decreased renal
mtDNA mutation frequency and a decreased level of glomerular oxidised guanosine [48].
Despite the strong association between DKD and oxidative damage, the therapeutic potential of
antioxidants is uncertain. Meta-analyses of published clinical trials suggest positive effects [63,64],
but benefits may be limited to early-stage DKD [63] and could perhaps be enhanced by prolonged
administration [64]. It is unclear if added antioxidants are able to reach the ROS sources, which
complicates the interpretation of disappointing trial results. Avoiding the accessibility issue, stimulation
of endogenous antioxidant defences by pharmacological activation of Nrf2 with bardoxolone methyl,
may indeed improve kidney function [65], but the cardiotoxicity of this drug has stopped its clinical
use [66]. When the antioxidant co-enzyme Q10 (ubiquinone) is targeted to mitochondria through
conjugation to a triphenylphosphonium moiety, it protects against DKD in diabetic db/db mice [67].
Renoprotection offered by this MitoQ compound appears to arise from a mitochondrial uncoupling
effect, not an antioxidant one [67]. Notably, uncoupling of oxidative phosphorylation will tip the
cellular bioenergetic balance to energy expenditure, thus establishing an oxidised environment that
disfavours ROS formation. Lack of positive clinical trial results may also reflect possible involvement
of ROS with kidney physiology, which will likely be disturbed by antioxidants. It is worth emphasising
in this respect that kidney function is regulated by insulin [68], and that renal insulin sensitivity is lost
early in DKD [21,22]. Although speculation, antioxidants may inadvertently increase the risk of renal
failure if ROS were equally important for insulin signalling in kidney as in skeletal muscle [54].
An alternative take on the disappointing clinical antioxidant trials is based on mitochondrial
hormesis [69]. Mitohormesis is defined as an adaptive cellular response to mild mitochondrial
stresses that render cells more resilient when exposed to subsequent, more severe, episodes of the
same stress [70]. In the case of mild oxidative stress, mitochondrial ROS are thought to trigger an
endogenous antioxidant defence that offers long-lasting protection against more intense future oxidative
stress. Added antioxidants are expected to interfere with this hormetic response, as exemplified
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by their adverse influence on the health-promoting, ROS-mediated, effects of physical exercise [71].
It is conceivable that kidney cells safeguard themselves against oxidative stress by mitohormesis,
and that added antioxidants compromise this endogenous defence mechanism. However, chronic
administration of antioxidants should be able to compensate for an inappropriate endogenous response
to oxidative stress, as indeed indicated by clinical trials [64]. In any case, the suggested potential
of promoting mitochondrial superoxide production in DKD therapy [69] is not clear, as possible
mitohormesis would have been compromised because of exogenous antioxidants, not because of an
intrinsic inability of renal cells to produce ROS. Even experimental DKD models that exhibit relatively
low ROS levels show signs of oxidative damage, i.e., renal mtDNA mutations and glomerular oxidised
guanosine [48]. In this context, it is worth emphasising that a high mitochondrial respiratory activity
does not necessarily imply a high rate of ROS production. As noted above, it is the reduction potential
of redox enzymes that dictates ROS formation [52]. This potential is at least partly set by the balance
between nutrient supply and energy expenditure. If driven by a high ATP demand, respiration will
likely cause limited ROS production.
3. Skeletal Muscle Insulin Resistance
Loss of systemic insulin sensitivity is an important feature of the metabolic syndrome, and
obesity-related insulin resistance of skeletal muscle and the liver has been studied intensively. Although
pathological mechanisms are incompletely understood, supraphysiological fatty acid levels are broadly
accepted culprits, and changes in mitochondrial activity are widely recognised [2]. Irrespective of
obesity, skeletal muscle can also lose insulin sensitivity as a consequence of kidney failure. In this
section, we argue that this uraemic muscle insulin resistance may arise against a background of
imbalanced cellular bioenergetics similar to that more commonly associated with obesity (cf. [16]).
3.1. Obesity
The causality of mitochondrial involvement in nutrient-induced insulin resistance has been
debated for some time [72,73], and the dispute is ongoing [74]. There is direct evidence from studies
involving humans with congenital insulin receptor signalling defects, that lowered mitochondrial ATP
synthesis capacity can follow from insulin resistance [75]. As we have discussed in detail recently [16],
it is less evident to what extent mitochondrial respiratory dysfunction causes loss of insulin sensitivity.
Insufficient mitochondrial capability to deal with nutrient excess in obesity has been suggested to
produce lipid metabolites and ROS that interfere adversely with insulin signalling paths (Figure 2).
Against this notion, it has been reasoned that muscle has a considerable spare oxidative capacity,
in both lean and obese subjects, that should suffice to burn large nutrient loads fully. However,
ATP fluxes are predominantly demand-driven in muscle and other tissues, thus engagement of the
mitochondrial oxidative capacity depends on cellular energy demand. Indeed, mitochondrial models
of obesity-related insulin resistance all involve harmful metabolites that only accumulate when nutrient
supply exceeds energy expenditure [16]. It is thus crucial to evaluate mitochondrial dysfunction in the
context of ATP consumption. When the energy demand of different experimental models is taken into
account, many discrepancies in the literature are thus readily reconciled [76].
Regarding the ‘mitochondrial causality’ debate, it is worth noticing that a low mitochondrial
ATP synthesis rate does not necessarily reflect an intrinsic oxidative phosphorylation defect, but
could be an adaptation to altered energy demand, as obese subjects tend to be less physically active
than lean individuals. Moreover, cellular stress responses that are induced by nutrient excess and
pro-inflammatory cytokines will likely change energy demand. Although stress responses may be
expected to increase (not decrease) mitochondrial ATP synthesis activity, it is conceivable that it perturbs
the hierarchy of ATP-consuming processes [77]. For instance, less ATP may be allocated to processes
that underpin general cell maintenance, or such processes may indeed be directly compromised
by nutrient excess. Consistently, we have demonstrated that palmitate and stearate lower the rate
of de novo protein synthesis in cultured rat myocytes, which coincides with a decreased rate and
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efficiency of oxidative ATP synthesis and with attenuation of insulin-sensitive glucose uptake [78].
The mitochondrial and glucose uptake effects of fatty acids are also observed in human myocytes [78].
Moreover, cycloheximide-sensitivity of coupled mitochondrial respiration is lowered in both human
and rat muscle cells, which demonstrates that the energy demand linked to protein synthesis is
decreased [78]. Notably, insulin resistance per se may lower energy demand, as insulin will be less able
to stimulate ATP-consuming anabolic processes.
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Figure 2. Skeletal muscle insulin resistance. Obesity and CKD cause common stresses that impair
insulin signalling by inhibiting IRS1 and AKT2, and thus attenuate the effect of insulin on the cellular
activities listed in Figure 1. Metabolic acidosis affects insulin signalling in a similar way, but is restricted
to CKD.
3.2. Uraemia
It has been recognised for some t me that kid ey disease can cause loss of keletal muscle insulin
sensitivity [79,80]. This uraemic muscle insulin resistance emerges early in CKD [81] and indeed
manifests itself in patients with inherited forms of the disease before symptoms of renal failure are
apparent [82]. Although the pathological mechanism is presently unclear, the insulin resistance has
been attributed to changes in insulin signalling that occur downstream from the insulin receptor [83–85]
in the insulin receptor substrate (IRS), phosphatidylinositol-3-kinase (PI3K) and protein kinase B (AKT)
pathway [86]. The same signalling components are thus affected in uraemia as in obesity (Figure 2).
Effectors that alter insulin signalling in CKD have not been established conclusively [17], but may well
be similar to the culprits behind nutrient-induced skeletal muscle insulin resistance (Figure 2), i.e.,
lipid metabolites and ROS. This may seem counter-intuitive when considering that uraemic muscle
insulin resistance manifests itself irrespectively of obesity [82] and that renal failure tends to lower
fat mass [87]. However, changes in lipid metabolism seen in CKD do resemble those observed in
obesity, including a raised level of circulating free fatty acids [88]. Moreover, macrophage infiltration
of adipose tissue in lean CKD patients causes inflammation that is similar to that seen in obese subjects
with normal kidney function [89,90]. This inflammation contributes to chronic oxidative stress in
uraemia [91,92], and both inflammation and oxidative stress have indeed been implicated in the loss of
muscle insulin sensitivity in CKD [17]. Additional consequences of renal failure that can cause muscle
insulin resistance include a perturbed blood pH regulation [93,94] and accumulation of toxins because
of impaired renal clearance [95]. These uraemic retention molecules have attracted interest in particular
as aggravators of CKD and its comorbidities [96,97]. For instance, p-cresyl sulphate is associated with
loss of insulin sensitivity of cultured myotubes, as it interferes with the phosphorylation of IRS1 [98].
Precursors of p-cresyl sulphate and related toxins such as indoxyl sulphate are formed during amino
acid metabolism in intestinal bacteria, and their accumulation is thus influenced by the composition of
the gut microbiome, which changes in CKD [99]. Notably, the toxicity of these compounds arises from
the inflammation and oxidative stress they cause in target tissues [100,101]. Similarly, urea that builds
up in CKD is believed to cause insulin resistance because of oxidative stress [102].
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When produced excessively in obesity, hydrogen peroxide causes muscle insulin resistance
via (indirect) inhibition of IRS1 [54,103]. Generally, formation of this ROS is only pathologically
high when nutrient supply exceeds energy demand [16]. Such imbalanced bioenergetics are indeed
characteristic of obesity, but are not necessarily a feature of CKD patients, many of whom are non-obese.
However, the loss of adipose mass in kidney failure [87] coincides with accumulation of ectopic fat in
many tissues, including skeletal muscle [98,104,105]. The balance between fuel supply and energy
expenditure may thus well be perturbed at the cellular level in CKD, and thus permit high ROS
formation. It is furthermore conceivable that a perturbed cellular bioenergetic balance causes build-up
of lipid metabolites that lower insulin signalling. In this respect, mitochondrial insufficiency has
been suggested to preclude complete lipid oxidation and thus cause uraemic skeletal muscle insulin
resistance [99,106]. Decreased muscle mitochondrial respiratory capacity has indeed been reported in
patients with CKD [20,90,107] and in models of kidney disease [90,108,109], but has not been linked
directly to insulin resistance. As discussed in the context of obesity [16], low mitochondrial respiration
may thus be a consequence of lost insulin sensitivity in uraemia rather than a cause.
4. Skeletal Muscle Wasting
The quality of the life of many CKD patients is compromised by frailty, particularly during
the later stages of renal failure [110]. This frailty emerges at least partly because of changes in
skeletal muscle mass and function that, collectively, are labelled as uraemic myopathy [111] or
sarcopenia [112], the latter to reflect the progressive and cumulative nature of CKD effects on skeletal
muscle [112]. Indeed, the muscle of CKD patients becomes increasingly weak as the disease progresses,
in terms of power output, endurance as well as exercise tolerance [112]. Moreover, muscle tissue
mass is lost because of a decreased size (atrophy) and number (hypoplasia) of muscle fibres [112].
General inactivity of CKD patients [113] does not fully explain this muscle weakness and muscle
wasting, as both locomotory and non-locomotory muscles are affected [114]. Consistent with the
very early manifestation of insulin resistance in CKD [81] and with the cumulative nature of its
deleterious effects [112], defected insulin signalling has been implicated in the aetiology of uraemic
myopathy [85,86,115]. This puts conditions that dampen insulin sensitivity (cf. Section 3.2) firmly in
the mechanistic frame, and oxidative stress [111], inflammation [116], metabolic acidosis [117] and
toxic uraemic retention molecules [101] have indeed all been linked to uraemic myopathy. Notably, lost
insulin sensitivity in uraemia perturbs skeletal muscle proteostasis, as it upsets the balance between
protein synthesis and protein breakdown [5,118]. Muscle proteolytic flux produces glucogenic amino
acids used to fuel gluconeogenesis in the liver and kidney [119]. To maintain skeletal muscle mass, this
protein turnover is compensated by de novo protein synthesis [120]. Defects in the IRS1-PI3K-AKT
insulin signalling pathway (Figure 2) have been suggested [5] to lower protein synthesis and to permit
proteolysis by activating the Forkhead box O (FOXO) transcription factors that regulate expression of
genes involved in proteasome- and lysosome-mediated protein breakdown (Figure 1).
Protein synthesis [121] and protein breakdown [122] are both energy-demanding processes. It is
thus perhaps not surprising that perturbed proteostasis has been linked to mitochondrial dysfunction.
Compromised skeletal muscle bioenergetics have been associated with uraemic frailty and myopathy
for some time, as it has been shown that the phosphocreatine recovery time after exercise is longer in
the skeletal muscle of end-stage CKD patients than in healthy subjects, suggesting a relatively low
ATP synthesis capacity [123–125]. Consistently, the activity of various energy metabolic enzymes
is comparably low in the muscle of CKD patients [126–129], as is the myocellular mitochondrial
volume density and mtDNA copy number [130]. Deleterious uraemic effects on muscle mitochondrial
mass have also been observed in CKD mouse models [109], and in both clonal and primary mouse
myotubes exposed to serum from such models [131]. Exposure to uraemic serum also attenuates
mitochondrial biogenesis and ATP synthesis in cultured myotubes [131]. Decreased mitochondrial
mass furthermore associates with increased autophagy, both in CKD patients [130] and mice [131].
Concomitant with a decreasing mitochondrial mass of muscle cells, PBMCs from patients with CKD
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have a decreased mtDNA content [130,132]. As in DKD, mitochondrial dysfunction thus appears to be
a systemic aspect of CKD (cf. Section 2.1). Notably, however, DKD is associated with an increased (not
decreased) level of circulating mtDNA that appears non-functional [50]. The decline in the mtDNA
concentration of PBMCs in uraemia is proportional to the severity of kidney failure [130], and thus
suggests progressive loss of mitochondrial activity as CKD develops. Indicative of causal involvement
in uraemic myopathy, muscle mitochondrial density decreases before symptoms of muscle weakness
emerge [130]. Non-invasive spectroscopic measurements of hand skeletal muscle bioenergetics in
non-diabetic CKD patients with preserved physical performance have shown increased muscle oxygen
uptake that is not used to make ATP [133]. It is unclear if this uncoupled mitochondrial respiration is
an early pathological feature of CKD [133] that triggers a mitochondrial density decline, or that it is
specific to muscle type.
The similarity of insulin signalling defects in uraemic and obese milieus (Figure 2) raises the
question as to why skeletal muscle wasting seems more prominent in CKD than in obesity. This
apparent discrepancy may just reflect the notion that insulin resistance is not the sole requirement
for perturbed proteostasis in CKD (cf. [134]). Metabolic acidosis is, for example, a feature of uraemia
that not only impairs insulin signalling [93,94], but also directly inhibits protein synthesis and directly
stimulates proteolysis [117]. However, the relatively prominent muscle wasting in CKD could be
interpreted differently. For instance, it is conceivable that pancreatic beta cells are less able to
compensate for insulin resistance in CKD (and other muscle-wasting states) than in obesity [9], perhaps
because of harmful effects of uraemic retention molecules on the insulin secretion from pancreatic beta
cells [95]. Retention molecules that impair beta cell activity have indeed been reported and include
3-carboxy-4-methyl-5-propyl-2-furanopropanoic acid (CMPF) [135,136] as well as urea [137]. Notably,
CMPF has been suggested to predict whether patients with prediabetes progress to T2D [138], which
offers the possibility that the propensity of people with obesity-related insulin resistance to develop
T2D is dictated by their kidney function.
5. Conclusions
Multiple aspects of the metabolic syndrome have been associated with bioenergetic failure, and
mitochondria are, possibly, attractive therapeutic targets to treat metabolic disease. The reports we
have reviewed above indicate two main mitochondria-related observations that are common to the
pathologies we have discussed. Firstly, it appears that the oxidative capacity of skeletal muscle is
decreased in obesity (cf. [16]) and in CKD [20,90,107–109]. Similarly, the mitochondrial respiratory
capacity of different kidney cell types (and PBMCs) is lowered in DKD [50,51]. Under pathological
conditions, in which respiration is actually increased—for example in kidney and skeletal muscle
at the onset of DKD and CKD, respectively—oxygen consumption appears to have been uncoupled
from ATP synthesis [39,133], which may be related to oxidative stress. Pharmacological strategies
that boost oxidative phosphorylation may thus have therapeutic potential. It will be important to
confirm, however, that the generally decreased ATP synthesis capacity is indeed due to intrinsic
mitochondrial defects, as it cannot be excluded that mitochondrial ATP supply declines in response
to pathological changes in energy demand. Secondly, it transpires that oxidative stress features in
the loss of insulin sensitivity of both the muscle and kidney. Obesity is characterised by imbalanced
bioenergetics that raise ROS generation sufficiently to impair muscle insulin signalling [54]. DKD
associates with oxidative stress [55], and it is thus plausible that renal insulin resistance is an early
consequence of the excessive ROS production in the kidney caused by hyperglycaemia. Similarly, ROS
may play a causative role in the loss of muscle insulin sensitivity in CKD, since most factors that prevail
in the uraemic milieu also induce oxidative stress [17]. Antioxidant therapies may be successful in
preventing insulin resistance and linked pathologies, but the molecular nature and cellular origin of the
harmful ROS need to be confirmed to allow specific drug targeting. Moreover, possible involvement
of ROS in insulin signalling—and other physiological processes—needs to be firmly established to
rationalise antioxidant strategies.
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